This analysis examines Advanced Enzyme (ADVENZYMES) through the lens of its financial statements, valuation metrics, and institutional ownership patterns.
Advanced Enzyme Revenue Trend
Year-over-year, Advanced Enzyme grew revenue by 17.1% — from ₹637 Cr in FY2025 to ₹746 Cr in FY2026.
Revenue compounded at 9.8% annually over 10 years for Advanced Enzyme. It's a reasonable growth rate that's roughly kept pace with the broader market.
At ₹746 Cr in annual revenue, Advanced Enzyme is one of the smaller players in the pharmaceuticals space.
Revenue has moved in the same direction for 10 years running, suggesting the growth trend has structural legs.
| Year | Revenue | YoY % |
|---|---|---|
| FY2026 | ₹746 Cr | +17.1% |
| FY2025 | ₹637 Cr | +2.1% |
| FY2024 | ₹624 Cr | +15.4% |
| FY2023 | ₹541 Cr | +2.1% |
| FY2022 | ₹529 Cr | — |
View Advanced Enzyme's full 10-year revenue trend with CAGR analysis →
Advanced Enzyme Profitability
Net profit for Advanced Enzyme climbed 32.4% to ₹174 Cr in FY2026.
Margins tell a good story: net profit margin moved up to 23.3% from 20.6%.
The diluted EPS figure moved up to ₹15.06 in FY2026, against ₹11.71 posted in FY2025.
Is Advanced Enzyme Undervalued
Advanced Enzyme shares are currently trading at ₹323.75.
Craytheon calculates intrinsic value using the P/E Ratio, DCF, and EPS Growth models. All three appear in the Valuation Models cards below.
Valuation Models
Advanced Enzyme Shareholding Pattern
Promoter holding is steady at 43.2% — no buying or selling over the past 4 quarters.
Foreign institutional investors (FIIs) held 26.7% as of June 2026, up from 25.4% a year ago.
DII holding is at 4.8%, down from 6.4% in the year-ago quarter.
| Quarter | Promoter | FII | DII | Public |
|---|---|---|---|---|
| Jun 2026 | 43.2% | 26.7% | 4.8% | 25.3% |
| Mar 2026 | 43.3% | 25.5% | 5.4% | 25.8% |
| Dec 2025 | 43.0% | 25.9% | 5.5% | 25.6% |
| Sep 2025 | 43.1% | 25.4% | 6.4% | 25.1% |
Track quarterly shareholding changes for Advanced Enzyme →
Advanced Enzyme Balance Sheet
Proportional view as of 3 Aug 2026. Hover blocks for details.
Assets
Liabilities & Equity
FY2026 total assets: ₹18.39B (up 13.4% YoY from ₹16.21B).
Top categories: Cash & ST Investments (37.7%), Intangibles & Goodwill (22.6%), Property, Plant & Equipment (17.8%).
Of the ₹18.39B in liabilities and equity, 91.5% is shareholder equity, 1.7% is interest-bearing debt, and 6.7% is operating liabilities. Over the year, debt is down 18.7% and equity is up 14.6%.
Balance sheet composition — FY 2026
| Category | Value |
|---|---|
| Cash & ST Investments | 6.93B |
| Receivables | 1.45B |
| Inventories | 1.77B |
| Property, Plant & Equipment | 3.27B |
| Investments | 640,000 |
| Intangibles & Goodwill | 4.16B |
| Other Assets | 804.32M |
| Category | Value |
|---|---|
| Equity | 16.83B |
| Short-term Debt | 203.53M |
| Long-term Debt | 116.56M |
| Trade Payables | 399.59M |
| Other Liabilities | 836.71M |
Advanced Enzyme Key Highlights
Here's the bottom line on Advanced Enzyme (ADVENZYMES) based on the latest available financials.
Revenue of ₹746 Cr in FY2026, up 17.1% year-over-year.
Long-term revenue has been compounding at 9.8% annually over 10 years.
The company is profitable, with a net margin of 23.3% and net income of ₹174 Cr.
Unlock Full Analysis
See the full picture — Craytheon tracks 10 years of financial data with interactive charts, growth trends, and three valuation models for Advanced Enzyme.